U.S. Psychedelic Use and Microdosing in 2025: RAND probability survey estimates past-year use and microdosing for multiple psychedelics

U.S. adults used multiple psychedelics in 2025, with psilocybin reported as the most common in the past year. RANDs 2025 Psychedelics Survey, fielded in September 2025 with a probability-based, nationally representative sample of 10,122 adults (age 18+), estimates past-year use of 11 psychedelic substances. Psilocybin was reported by about 11 million U.S. adults, followed by MDMA (or MDA) and Amanita muscaria mushrooms, then ketamine and LSD. Microdosing was widespread among people who used psilocybin, LSD, or MDMA in the past year. RAND estimates that about 10 million U.S. adults microdosed one of these substances, and that most past-year psilocybin use days involved microdosing. The report presents population-weighted day counts and shares of microdosing days, while emphasizing that microdosing status is based on self-reports and that there is no official standard microdose definition.